Title
Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed
Document Type
Article
Publication Date
2007
Abstract
Objective: To examine treatment with psychostimulant medicines for attention deficit hyperactivity disorder (ADHD) in children (3-17 years) within Western Australia (WA) during 2004.
Methods: Using whole-populationbased administrative pharmacy data for 2004, age-specific prevalence of children treated with dexamphetamine and methylphenidate was determined. Treatment with immediate-action and sustained-release stimulants was also examined. Average daily dose (absolute and relative to body weight) of dexarnphetamine, methylphenidate and total stimulant medication was also calculated.
Results: 9,658 children from 3-17 years (23.5 per 1,000 child population) were treated with stimulant medication for ADHD during 2004. Age-specific prevalence of treatment increased rapidly from three to eight years to peak at 14 years. The male-to-female ratio of stimulant treatment was 4.1. Child prevalence of treatment with dexamphetamine, methylphenidate or combined therapy was 16.4, 8.9 and 1.7 Per 1,000 children, respectively. Most children were treated with immediateaction stimulants (16.9 per 1,000 child population), with fewer using sustainedrelease medicines (4.0 per 1,000 child population).
Conclusions: The prevalence of stimulant medication use for the treatment of ADHD in WA children is 2.4%, with males accounting for the majority of treated patients. Most children were treated with dexamphetamine. Prescribing of methylphenidate, sustained-release stimulants or combined medication therapy was less common. Age-related trends in prescribed daily dose differed for dexamphetamine and methylphenidate.
Recommended Citation
Preen, D. B., Calver, J., Sanfilippo, F., Bulsara M., & Holman, D. J. (2007). Patterns of psychostimulant prescribing to children with ADHD in Western Australia: Variations in age, gender, medication type and dose prescribed. Australian and New Zealand Journal of Public Health, 31(2), 120-126. doi: 10.1111/j.1753-6405.2007.00028.x
Comments
Due to copyright restrictions this article is unavailable for download.
Staff and Students of the University of Notre Dame Australia may access the full text of this article here
This article may be accessed from the publisher here
The Australian and New Zealand Journal of Public Health may be accessed from the National Library of Australia here